Arrowhead Pharma, Nutanix, Retail Sector & Broad Markets Rise! Vista Partners Daily Market Recap 11/26/19

By John Heerdink LinkedIn

Big Movers

Arrowhead Pharmaceuticals, Inc. (ARWR), a company that develops medicines that treat intractable diseases by silencing the genes that cause them rose +18.79% today closing at $67.70/share. Yesterday after the close the company hosted the fiscal year 2019 conference call to review their progress and the market seemed to react well to there updates.

The SPDR S&P Retail ETF (XRT 44.84, +0.27, +0.6%) as many retail reports surfaced on the positive side. Best Buy Co., Inc. (BBY $81.57, +9.9%), Burlington Stores, Inc. (BURL $225.97, +8.5%), & Dick’s Sporting Goods, Inc, (DKS $46.77, +18.6%) all knocked it out of the park beating expectations and raising guidance.

Nutanix, Inc. (NTNX), a cloud storage software company beat Wall Street revenue quarterly expectations of $306.4M coming in at $314.8M. NTNX shares closed at $33.47, +16.47.

Broad Markets

The broad markets moved up across the board acheiving record new highs. Somewhat positive rhetoric flowed from the US-China Trade war meetings again today while the markets dieted on a steady flow of positive earnings reports out of the retail sector.  Fed Chair Jerome Powell also issued a statement in a speech today that interest rates would likely stay constant as they are currently at a 1.50% to 1.75% range will ‘likely to remain appropriate. The Dow closed up +55.21 points +.20% closing at 28,121.68. The S&P 500 ended today’s session +6.88 points or +.22% as it closed at 3,140.52. The S&P 500 real estate (+1.4%) & consumer staples (+0.8%) sectors led the pack while the energy (-1.0%) sector (-0.4%) led the bottom group today.  The Nasdaq closed at 8,647.93 up +15.44  points, +.18%. The Russell 2000, the small-cap stock market index representing the bottom 2,000 stocks in the Russell 3000 Index also rose today ending the day +.14%, +2.33 points at 1,624.23.

The U.S. Dollar Index weakened ending at 98.31. The 2-yr Treasury yield closed at 1.58% up 3 basis points & the 10-yr yield finished down 2 basis points at 1.74% today.

Oil prices closed at $58.30/bbl, +.6%. Chevron (CVX) closed at $117.79/share,-.50%, Exxon (XOM) closed at $68.74/share, -.25%. Chevron reported earnings recently of $.75, beating estimates of $.681 per share. Exxon Mobil (XOM) reported earnings recently of $1.36, missing estimates of $1.564 per share. Occidental Petroleum (OXY) closed at $38.57/share -3.41%.

Gold prices closed up at $1,462.30/oz%. Silver closed at $17.14/oz. Hecla Mining Company (HL) closed at $2.40/share +.2.13% after reporting its Q3 2019 earnings Thursday Nov. 7th, which highlighted their Adjusted EBITDA of $69.8 million, approximately 40% lower cash cost per silver ounce and all-in sustaining cost (“AISC”) per silver ounce, in each case net of by-product credits compared to the third quarter of 2018, free cash flow of $28.8 million generated and a tentative agreement for their Lucky Friday Mine. (See complete story). Post the quarter BMO upgraded HL to a market perform. First Majestic Silver (AG) closed lower at $10.82/share off +3.94% after recently reporting their Q3 2019 earnings where their CEO Keith Neumeyer highlighted that they added $21.4M to their treasury during the quarter as a result of strong production from San Dimas and Santa Elana mines.

Volatility bets moved down again today.  The CBOE Volatility Index (VIX) closed at $11.54/share -2.78% or -$.33/share. The 2x leveraged ETF (TVIX) closed at $6.12/share -3.32% or -$.21/share and traded tightly between $6.05 and $6.31 today.

Economic Reports

  • On Monday, we did not receive any points of significance.
  • On Tuesday, a number of economic points surfaced. We received the new home sales report for October which showed a drop of -.7% month/month to a seasonally adjusted annual rate of 733k units while on a year/year basis the new home sales report showed an increase of +31.6%. The Conference Board’s Consumer Confidence Index report for November decreased to 125.5  from 125.9 in October. The Advance International Trade in Goods report for October confirmed a tightening od the deficit to $66.5B from $70.5B in September. The Advance Retail Inventories report showed that it increased were by +.3%. The Advance Wholesale Inventories report in October showed a rise of +.2%. The FHFA Housing Price Index for September jumped +.6%. The S&P Case-Shiller Housing Price Index for September rose +2.1%.

Healthcare

The S&P 500 healthcare sector closed at 1147.21 -.07%. UnitedHealth Group (UNH) closed at $281.40/share -.45% after a recent Q3 earnings beat on 10/15/19 & Walgreens Boots Alliance (WBA) closed at $59.63/share -1.71%. Walgreens reported earnings on 10/28/2019 of $1.43/share, missing estimates calling for $1.451 per share. Recently reports surfaced that publicly traded private equity firm KKR (KKR $29.65, +.37%) is preparing a buyout plan. Cigna (CI) closed at $200.37/share, -1.72%.

INVO Bioscience, Inc. (IVOB), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System (pictured above), recently announced that it has entered into commercialization agreements in the continent of Africa, covering Nigeria, Uganda, Sudan, and Ethiopia, to distribute the revolutionary INVOcell system. The agreements represent INVO Bioscience’s initial entry into the highly populated infertility markets in Africa. According to research, approximately 31% of Nigerian couples fail to conceive a child after 12 months of unprotected sex—a rate at least as high as in the West. Across the continent, infertility is on the rise. Infertility comes with devastating social, cultural, emotional and economic consequences for young couples in Africa. However, access to assisted reproductive services remains a big challenge as traditional IVF treatment is limited in many areas of Africa. (READ complete story)

IVOB held a live investor webcast on Thursday, November 21, 2019, to discuss the results and provide investors an overview of the Company and its strategy. A webcast replay will be available for 90 days in the Investor Relations section of the Company’s website at https://invobioscience.com/investors/.

Biotech

The Ishares Nasdaq Biotechnology ETF (IBB) moved +.19% closing at $118.48 & the NYSE Arca Biotech Index (^BTK) closed at 4,955.39, +.10%.

Johnson & Johnson (JNJ) closed at $137.17/share, -.01%, Merck & Co (MRK) closed at $87.34/share, +1.91%, Pfizer (PFE) closed at $38.29/share, -1.01%. Merck (MRK) reported earnings on 10/29/2019 of $1.51, beating estimates of $1.28 per share. Pfizer (PFE) reported earnings on 10/29/2019 of $.75, beating estimates of $.644 per share.

Atossa Genetics (ATOS) closed trading at $1.33/share, -3.86%. Recently, Atossa and The Dr. Susan Love Research Foundation announced that the Institutional Review Board (IRB) has approved a Phase 2 clinical study of Atossa’s intraductal microcatheter technology for the administration of fulvestrant in patients with early-stage breast cancer or ductal carcinoma in situ (DCIS). Susan Love, M.D., inventor of the technology, will advise Atossa as it conducts the trial. Atossa also entered into a clinical trial agreement with a major research university named in the 8k filing that Atossa filed on 10-14-2019 to conduct their Phase 2 clinical study of Atossa’s intraductal microcatheter technology for the administration of fulvestrant in patients with early-stage breast cancer or ductal carcinoma in situ (DCIS). Atossa Genetics is the owner of issued patents, pending patent applications, and medical device FDA 510(k) premarket notifications related to the treatment of breast conditions, including breast cancer and DCIS.

“We have contracted with a world-class teaching, research, and healthcare organization based in the United States to conduct this study,” commented Steven C. Quay, Ph.D., M.D., CEO and President of Atossa. “Atossa’s intraductal technology was invented by Dr. Love and subsequently acquired by Atossa. We are honored that Dr. Love has agreed to work with us on this important new study. This work begins as Atossa increases its corporate focus on its proprietary Endoxifen for the reduction of mammographic breast density.” READ the complete story here.

This week, Atossa announced financial results for the third quarter ended September 30, 2019, and provided an update on recent company developments. Steven C. Quay, M.D., Ph.D., Atossa Genetics’ President, and CEO commented, “In the third quarter we made substantial headway in advancing the development of our lead drug candidate – Endoxifen – as we turn our concentration towards treating mammographic breast density (MBD). We recently announced meeting all objectives in our Phase 1 study of the modified-release tablet form of oral Endoxifen, which paves the way toward advancing our modified-release tablet into Phase 2 studies. The final analysis of the results demonstrated that the modified-release tablet had no treatment-related side effects that were rated as moderate or severe in intensity, strongly supporting the continued development of this proprietary formulation. We also initiated our Phase 2 clinical study of Atossa’s intraductal technology for the administration of fulvestrant in patients with early-stage breast cancer with a major institution and supported by the Dr. Susan Love Research Foundation. Many of the approximately 64,000 women with ductal carcinoma in situ (DCIS) who opt for ‘watchful waiting’ rather than extensive surgery could benefit from a gentler, intermediate treatment of DCIS with intraductal ablation with fulverstrant. Before the end of the year, we look forward to reporting several significant milestones: contracting with a clinical research organization for our Phase 2 study of oral Endoxifen to treat MBD, completing additional pre-clinical work of our cell-based therapy candidate and our intraductal technology, as well as reporting additional results from our recently completed clinical study of our modified-release form of Endoxifen tablets.” Read Complete Story.

Tech, Entertainment & Beyond

Apple (AAPL) closed at $264.29/share, -.78% as optimism continues to grow with regard to the new iPhone models and new streaming entertainment offering, Alphabet (GOOG) closed at $1,313.55/share, +.52%, Facebook (FB) closed at $199.97/share, -.41%, Microsoft (MSFT) closed at $152.03/share +.53%, NVIDIA (NVDA) closed at $217/share, -1.9% and recently reported Q3 results beating Wall Street’s Q3 expectations however they did not meet on their forward-looking outlook views. IBM closed at $135.09/share, -.65% as it recently missed wall street Q3 expectations. Cisco Systems (CSCO) was down -.31% finishing at $45.31/share after reporting results this week that missed expectations & lowered guidance. Goldman Sachs (GS) ($222.45/share, -.13%) recently downgraded CSCO as it views that corporate spending on technology has weakened.

Disney (DIS) closed at $151.64/share, +1.30% after hitting a new 52-wk high of $153.41/share. Recently Disney beat quarterly expectations & announcing that they already have more than 10 million Disney+ subscribers which also beat analysts’ expectations of 8 million subscribers by the end of 2019.

Verizon (VZ) ($59.89/share, +.86%) recently announced that it will be giving the streaming service Disney+ to all new customers of Verizon for a year, and Netflix (NFLX) closed at $312.49/share, -.97%. Recently rumors surfaced that either/or both Carl Icahn & Bill Ackman have accumulated a large position in NFLX. Amazon (AMZN) closed at $1,796.94/share, +1.30%.

Streaming device maker Roku (ROKU) closed at $164.28/share, +3.92% after they recently reported earnings beating both top and bottom Wall Street expectations, but also reducing its profitability outlook for 2019 as a whole, adjusting it from $30M from $35M reflecting continued investing in the business and Q4 dataxu operations and acquisition expenses. The dataxu acquisition was announced to have been completed recently.

Boeing (BA) closed at $373.51/share, +.10% after their CEO’s recent testimony to the Senate and today’s new reported understanding that the 737 Max return is closer than thought.



Post View Count : 7190


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us